Tollys is a biopharmaceutical company located in Lyon, Ffance, focused on innate immunity & TLR3 receptor. Tollys discovered & patented a family of TLR3 agonists and selected TL-532, a structurally defined double-stranded RNA produced synthetically & highly specific to the TLR3 receptor. Tollys has raised a total of €6M in equity and received a grant of €1.5M from Bpifrance. Tollys plans to start clinical phase 1 trials with TL-532 in 2022.
41 quai Fulchiron 69005 Lyon
Targeted indications : Genitourinary cancers